SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Attention centers on Corvuss soquelitinib atopic dermatitis data, which bullish traders view as encouraging evidence for the drugs broader potential. The stocks sharp negative reaction to the presentation has prompted debate over whether investor expectations were overbuilt, with skeptics citing unanswered safety questions and longs blaming short selling.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines positive Phase 3 results for daraxonrasib and its FDA approval for metastatic pancreatic cancer remain the main focus, with traders weighing the drugs commercial potential against concerns about weaker results in some KRAS subgroups and emerging competitors. Discussion also centers on the upcoming earnings report and whether early launch performance can support the companys valuation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Strong quarterly results and managements outlook are drawing attention, with traders focused on advanced negotiations to supply natural gas to data centers and other large power users. The reaction is broadly bullish on growth prospects and rising distributions, though some investors are frustrated that the unit price has shown a muted response.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers

Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million.
Lexaria Bioscience (NASDAQ:LEXX) stockread more...

Silexion Doses First Patient In Phase 2/3 SIL204 Trial For Pancreatic Cancer

(RTTNews) - Wednesday, Silexion Therapeutics (SLXN) said the first patient has been dosed in its global Phase 2/3 trial evaluating SIL204 in patients with locally advanced pancreatic cancer (LAPC...

Biotech And Biomimicry Stocks Lighting Up the Market

Biotech and life-science stocks are commanding attention as a fresh wave of momentum sweeps through the sector, with Silexion Therapeutics (NASDAQ:SLXN), Kraig Biocraft Laboratories (OTCQB:KBLB), 10x Genomics (NASDAQ:TXG), Moderna (NASDAQ:MRNA), AbCellera Biologics (NASDAQ:ABCL), Viatris (NASDAQ:VTRS), and Twist Bioscience (NASDAQ:TWST) among today’s notable names.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million.
Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%read more...

Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On

Silexion Therapeutics shares jump after hours on positive SIL204 preclinical findings for KRAS-driven cancers.read more...

Biotech and Biologics Break Out: These Tiny Stocks Are Suddenly Dominating the Market Conversation

Emerging biotech and biologics names exploded onto traders’ radar Wednesday as a wave of clinical milestones, regulatory momentum, strategic acquisitions, and high-volume technical breakouts fueled aggressive speculation across the sector. $HCWB, $TGNT, $KBLB, $SLS, $RKDA, $ROIV, $SLXN

Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why

Equity

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.


TRIB, SLXN, STSS: Why Retail Chatter On 3 Nano-Cap Healthcare Stocks Exploded Over 6000%

“Compelling” results from a study, promising pre-clinical data and a public offering got Stocktwits investors buzzing on Tuesday.


Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures

Priced at $1.35 per share and warrant, the offering was below Wednesday’s closing price of $1.56.

5 Stocks Retail Investors Are Most Bullish On At Mid-Day

Retailers went overboard about a couple of biotech stocks and a MedTech name, among others on Wednesday.

Silexion Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery and development of treatments for KRAS-driven cancers. The company was founded on November 30, 2008 and is headquartered in in Modiin, Israel.

Silexion Therapeutics Corp

Bearish Sentiment

Biotech stocks remain a hot sector for retail traders on Stocktwits,&nbsp;which collectively boast over 3.45 million followers.&nbsp;In January, several biotech names saw explosive gains as investors bet on breakthrough treatments, key partnerships, and regulatory milestones.According to Stocktwits data, these five biotech stocks saw the highest surge in retail following this month.CARGO Therapeutics Inc. (CRGX) – 445% Jump In FollowersCARGO Therapeutics, a clinical-stage biotech company focused on cancer treatments, saw its stock collapse even as retail interest surged.&nbsp;In January, the FDA cleared its Investigational New Drug (IND) application for CRG-023, a novel tri-specific CAR T therapy designed to tackle relapse factors in B-cell malignancies.&nbsp;However, the company later announced it would discontinue a Phase II trial of its lead candidate, firi-cel, after an ad hoc safety analysis revealed an unfavorable benefit-risk profile.&nbsp;Wall Street analysts issued downgrades, and CARGO’s stock is on track to plunge more than 76% in January — its worst month since going public in November 2023.&nbsp;Short interest stands at 15.1%, according to Koyfin data.Sana Biotechnology Inc. (SANA) – 185% Jump In FollowersSana Biotechnology, which focuses on engineered cell therapies, captured investor attention with a potential&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sana-biotech-stock-triples-after-type-1-diabetes-trial-data/chGBWsVRZO">breakthrough</a> in type 1 diabetes.&nbsp;The company demonstrated earlier this month that its hypoimmune edits allowed islet cell transplant survival without immunosuppression.&nbsp;Analysts praised the findings, driving the stock up roughly 114% in January — its best month since its March 2021 market debut.&nbsp;Short interest is at 16.6%.Silexion Therapeutics Corp. (SLXN) – 92% Jump In FollowersSilexion, an oncology-focused biotech developing RNA interference therapies, gained momentum after releasing preclinical data on a second-generation siRNA candidate, SIL-204.&nbsp;The treatment&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/slxn-stock-hits-record-low-after-pricing-5m-offering/chGtwKoRng">showed</a> synergistic efficacy when combined with first-line chemotherapy for pancreatic cancer.&nbsp;Although the stock gained just 2% in January, it marked its best month since November.&nbsp;Short interest remains low at 2.4%.AEON Biopharma Inc. (AEON) – 81% Jump In FollowersAEON Biopharma is developing ABP-450, a botulinum toxin complex similar to Evolus’ Jeuveau, for medical indications such as chronic migraine.&nbsp;Retail traders appeared to buy the dip after AEON priced a $20 million public offering earlier this month, which initially sent shares tumbling.&nbsp;The stock is headed for a 77% drop in January, its worst month since going public via a SPAC merger in July 2023.&nbsp;Short interest is just 0.2%, according to Koyfin.Kairos Pharma (KAPA) – 78% Jump In FollowersKairos Pharma, a clinical-stage biopharmaceutical company, saw retail interest soar this month after breaking key resistance levels and securing crucial investments.&nbsp;The company is testing its lead candidate, ENV105 — which targets a protein linked to resistance in cancer treatments — in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for lung cancer.The stock gained momentum following CEO John Yu’s positive comments at an investor healthcare summit this month and the completion of a $3.5 million PIPE transaction.&nbsp;Kairos shares are set to decline 2.6% in January, marking their worst month since October.&nbsp;Short interest remains&nbsp;negligible at 0.1%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.

AEON Biopharma Inc. - Ordinary Shares - Class A

CARGO Therapeutics Inc

Kairos Pharma Ltd.

Sana Biotechnology Inc

Silexion Therapeutics Ltd

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.1452
Prev Close	$0.1423
Open	$0.1424
Dividend Yield	0.00%
50-Day Moving Average	$0.2842
Beta	1.95
Avg. Volume	29.02M
PE Ratio	0.00

52-Week High	$33.50
52-Week Low	$0.1401
Market Capitalization	$2.21M
EPS (Annual)	-$89.60
Price to Book	3.89
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLXN Fundamentals